A. V. Kulish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. V. Kulish has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Sergey Sergeevich Bagnenko
N. N. Petrov National Medical Research Center of Oncology; St. Petersburg State Pediatric Medical University
6 shared publications - Ilia A. Burovik
S.M. Kirov Military Medical Academy, Ministry of Defense of Russia
5 shared publications - Ekaterina A. Busko
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
4 shared publications - Stanislav A. Tiatkov
S.M. Kirov Military Medical Academy, Ministry of Defense of Russia
4 shared publications - Ksenia Vyacheslavovna Kozubova
ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» МЗ РФ
3 shared publications - Pavel Yurievich Grishko
N. N. Petrov National Medical Research Center of Oncology
3 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 2 (3, Suppl. ) , onmt_A14
Comparison of the Sensitivity of CT-Arteriohepaticography and Intravenous Contrast-Enhanced CT in Colorectal Cancer Liver Metastases After Neoadjuvant Chemotherapy
Introduction: The main method for preoperative assessment of colorectal cancer (CRC) liver metastases remains intravenous contrast-enhanced computed tomography (CT); however, its sensitivity is limited, especially for lesions smaller than 10 mm, and neoadjuvant chemotherapy further reduces it. The characteristic CT appearance of a metastasis is hypodensity in the portal phase and a rim of enhancement at the lesion edge, which can be enhanced by injecting contrast material directly into the hepatic arteries. CT-arteriohepaticography (CT-AHG) is potentially more effective, including during drug treatment, but data on its sensitivity after chemotherapy are virtually absent. Objective: To compare the diagnostic efficacy of CT-AHG and intravenous contrast-enhanced CT in the detection and characterization of CRC liver metastases in patients after neoadjuvant chemotherapy. Materials and Methods: This single-center prospective study included 22 patients with CRC and liver metastases who underwent both imaging methods prior to liver resection at the N.N. Petrov National Medical Research Center of Oncology. The unit of analysis was the lesion. The reference standard was targeted histological examination of each resected lesion. CT and CT-AHG were evaluated independently, using animated images, by radiologists with more than 5 years of experience, one for each "patient–method" pair. For each method, sensitivity, specificity, and predictive values with 95% Clopper–Pearson confidence intervals (CIs) were calculated for 129 included lesions. The difference in sensitivities was reported with 95% CI (patient-level bootstrap) and tested using McNemar's exact test. Results: With combined use of CT and CT-AHG (a lesion was considered positive if detected by at least one method), sensitivity was 80.8% [72.6–87.4], which was 10.0 percentage points (95% CI: +2.4 to +17.9) higher than the sensitivity of CT alone. Individually, sensitivity was 70.8% [61.8–78.8] for CT and 73.3% [64.5–81.0] for CT-AHG. The difference between them was −2.5 percentage points (95% CI: −9.5 to +6.8) and was not statistically significant (p = 0.66). For lesions smaller than 10 mm, sensitivity was 35.3% for CT versus 50.0% for CT-AHG; for lesions 10 mm or larger, sensitivity was 84.9% and 82.6%, respectively. Conclusion: The sensitivity of CT-AHG does not differ significantly from that of intravenous contrast-enhanced CT; however, the combination of methods improves sensitivity by 10.0 percentage points. Therefore, CT-AHG should be considered as a complement to CT, rather than a replacement for it.
- 21 September 2026
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 2 (3, Suppl. ) , onmt_A14
Open AccessComparison of the Sensitivity of CT-Arteriohepaticography and Intravenous Contrast-Enhanced CT in Colorectal Cancer Liver Metastases After Neoadjuvant Chemotherapy
Introduction: The main method for preoperative assessment of colorectal cancer (CRC) liver metastases remains intravenous contrast-enhanced computed tomography (CT); however, its sensitivity is limited, especially for lesions smaller than 10 mm, and neoadjuvant chemotherapy further reduces it. The characteristic CT appearance of a metastasis is hypodensity in the portal phase and a rim of enhancement at the lesion edge, which can be enhanced by injecting contrast material directly into the hepatic arteries. CT-arteriohepaticography (CT-AHG) is potentially more effective, including during drug treatment, but data on its sensitivity after chemotherapy are virtually absent. Objective: To compare the diagnostic efficacy of CT-AHG and intravenous contrast-enhanced CT in the detection and characterization of CRC liver metastases in patients after neoadjuvant chemotherapy. Materials and Methods: This single-center prospective study included 22 patients with CRC and liver metastases who underwent both imaging methods prior to liver resection at the N.N. Petrov National Medical Research Center of Oncology. The unit of analysis was the lesion. The reference standard was targeted histological examination of each resected lesion. CT and CT-AHG were evaluated independently, using animated images, by radiologists with more than 5 years of experience, one for each "patient–method" pair. For each method, sensitivity, specificity, and predictive values with 95% Clopper–Pearson confidence intervals (CIs) were calculated for 129 included lesions. The difference in sensitivities was reported with 95% CI (patient-level bootstrap) and tested using McNemar's exact test. Results: With combined use of CT and CT-AHG (a lesion was considered positive if detected by at least one method), sensitivity was 80.8% [72.6–87.4], which was 10.0 percentage points (95% CI: +2.4 to +17.9) higher than the sensitivity of CT alone. Individually, sensitivity was 70.8% [61.8–78.8] for CT and 73.3% [64.5–81.0] for CT-AHG. The difference between them was −2.5 percentage points (95% CI: −9.5 to +6.8) and was not statistically significant (p = 0.66). For lesions smaller than 10 mm, sensitivity was 35.3% for CT versus 50.0% for CT-AHG; for lesions 10 mm or larger, sensitivity was 84.9% and 82.6%, respectively. Conclusion: The sensitivity of CT-AHG does not differ significantly from that of intravenous contrast-enhanced CT; however, the combination of methods improves sensitivity by 10.0 percentage points. Therefore, CT-AHG should be considered as a complement to CT, rather than a replacement for it.
- Open Access
- 30 December 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (6)
CT Arteriography for Assessing Colorectal Cancer Liver Metastases After Systemic Drug Therapy
Введение. Колоректальный рак занимает третье место в структуре онкологической заболеваемости в мире, метастазы в печени обнаруживают у 25 % пациентов на момент первичной диагностики и у 50 % пациентов после резекции первичной опухоли. Цель. Предложить и апробировать методику КТ-артериогепатикографии для диагностики метастазов колоректального рака в печени после химиотерапии. Материалы и методы. В исследование включено семь пациентов с колоректальным раком и метастазами в печени после неоадъювантной химиотерапии. Всем пациентам выполнена КТ-артериогепатикография с внутриартериальным введением 40 мл йодсодержащего контрастного препарата (300-320 мг йода/мл) со скоростью 2 мл/с. Сканирование проводилось в две фазы: на 22 сек (семь пациентов) и 33-38 сек (шесть пациентов) от начала введения контрастного вещества. Оценивались наличие капиллярной фазы контрастирования, визуализация метастазов и периферического ободка контрастирования вокруг них, выраженность транзиторных участков артериального усиления печени (ТАУП). Результаты. Выявлено 19 метастазов печени. Капиллярная фаза контрастирования на 22 сек достигнута у четырех из семи пациентов (57 %), на 33-38 сек — у всех шести обследованных на этой фазе пациентов (100 %). Гиперваскулярный ободок контрастирования визуализировался у 15 необызвествленных метастазов (100 %) в обе фазы сканирования с одинаковой выраженностью. ТАУП отмечены у всех пациентов при сканировании на 22 сек с уменьшением выраженности к 33-38 сек. Заключение. Предложенная методика КТ-артериогепатикографии обеспечивает 100 % визуализацию периферического ободка контрастирования у необызвествленных метастазов колоректального рака после химиотерапии. Сканирование на 33-38 сек предпочтительнее из-за стабильного достижения капиллярной фазы и меньшей выраженности перфузионных артефактов при сохранении диагностической ценности ободка контрастирования.
- 30 December 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (6)
Open AccessCT Arteriography for Assessing Colorectal Cancer Liver Metastases After Systemic Drug Therapy
Введение. Колоректальный рак занимает третье место в структуре онкологической заболеваемости в мире, метастазы в печени обнаруживают у 25 % пациентов на момент первичной диагностики и у 50 % пациентов после резекции первичной опухоли. Цель. Предложить и апробировать методику КТ-артериогепатикографии для диагностики метастазов колоректального рака в печени после химиотерапии. Материалы и методы. В исследование включено семь пациентов с колоректальным раком и метастазами в печени после неоадъювантной химиотерапии. Всем пациентам выполнена КТ-артериогепатикография с внутриартериальным введением 40 мл йодсодержащего контрастного препарата (300-320 мг йода/мл) со скоростью 2 мл/с. Сканирование проводилось в две фазы: на 22 сек (семь пациентов) и 33-38 сек (шесть пациентов) от начала введения контрастного вещества. Оценивались наличие капиллярной фазы контрастирования, визуализация метастазов и периферического ободка контрастирования вокруг них, выраженность транзиторных участков артериального усиления печени (ТАУП). Результаты. Выявлено 19 метастазов печени. Капиллярная фаза контрастирования на 22 сек достигнута у четырех из семи пациентов (57 %), на 33-38 сек — у всех шести обследованных на этой фазе пациентов (100 %). Гиперваскулярный ободок контрастирования визуализировался у 15 необызвествленных метастазов (100 %) в обе фазы сканирования с одинаковой выраженностью. ТАУП отмечены у всех пациентов при сканировании на 22 сек с уменьшением выраженности к 33-38 сек. Заключение. Предложенная методика КТ-артериогепатикографии обеспечивает 100 % визуализацию периферического ободка контрастирования у необызвествленных метастазов колоректального рака после химиотерапии. Сканирование на 33-38 сек предпочтительнее из-за стабильного достижения капиллярной фазы и меньшей выраженности перфузионных артефактов при сохранении диагностической ценности ободка контрастирования.
- Open Access
- 5 November 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (5)
Role of Perineal Implantation of a Paraprostatic Spacer in Maintaining Erectile Function after Radiation Therapy
Введение. Повышение безопасности лучевого рака предстательной железы (РПЖ) — важнейшая задача современной радиационной онкологии. Разработка методики облучения, позволяющая снизить риски постлучевой эректильной дисфункции, направлена на решение данной задачи. Цель. Оценить механизмы снижения дозы на область сосудистых эректильных критических органов (ЭрКО) при лучевом лечении РПЖ, обусловленные промежностной имплантацией парапростатического биодеградируемого спейсера (ПБС). Материалы и методы. В исследование вошли 20 пациентов с верифицированным РПЖ, которым проводилась стереотаксическая лучевая терапия (СТЛТ) в суммарной очаговой дозе 36,25 Гр. На этапе предлучевой подготовки выполнено промежностное введение отечественного спейсера в объеме 6–8 мл. Для анализа дозиметрических изменений, обусловленных введением биополимера, у каждого пациента рассчитано по четыре (всего 80) плана: стандартный план (СП) до имплантации ПБС без снижения дозы на область сосудистых ЭрКО (СП-1), сосудосберегающий план (ССП) до имплантации ПБС (ССП-1), стандартный план после имплантации ПБС без снижения дозы на область сосудистых ЭрКО (СП-2) и сосудосберегающий план после имплантации ПБС (ССП-2). Результаты. Выявлено фактически полное отсутствие изменений в топографии верхушки предстательной железы относительно базальных структур полового члена. Значимых различий по величине радиационной нагрузки на область сосудистых ЭрКО при стандартном планировании (СП-1 и СП-2) независимо от использования ПБС получено не было. Дополнительная оптимизация, направленная на максимальное снижение дозы в рамках протокола сосудосбережения (ССП-1 и ССП-2), обеспечила существенное снижение дозы на область сосудистых ЭрКО по сравнению со стандартными планами, а имплантация ПБС позволила достигнуть наименьших показателей облучения внутренней половой артерии (р < 0,0001). Выводы. Промежностная имплантация ПБС позволяет повысить эффективность сосудосберегающей лучевой терапии РПЖ за счет временного смещения передней стенки прямой кишки относительно предстательной железы, что улучшает оптимизацию пространственного распределения дозы.
- 5 November 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (5)
Open AccessRole of Perineal Implantation of a Paraprostatic Spacer in Maintaining Erectile Function after Radiation Therapy
Введение. Повышение безопасности лучевого рака предстательной железы (РПЖ) — важнейшая задача современной радиационной онкологии. Разработка методики облучения, позволяющая снизить риски постлучевой эректильной дисфункции, направлена на решение данной задачи. Цель. Оценить механизмы снижения дозы на область сосудистых эректильных критических органов (ЭрКО) при лучевом лечении РПЖ, обусловленные промежностной имплантацией парапростатического биодеградируемого спейсера (ПБС). Материалы и методы. В исследование вошли 20 пациентов с верифицированным РПЖ, которым проводилась стереотаксическая лучевая терапия (СТЛТ) в суммарной очаговой дозе 36,25 Гр. На этапе предлучевой подготовки выполнено промежностное введение отечественного спейсера в объеме 6–8 мл. Для анализа дозиметрических изменений, обусловленных введением биополимера, у каждого пациента рассчитано по четыре (всего 80) плана: стандартный план (СП) до имплантации ПБС без снижения дозы на область сосудистых ЭрКО (СП-1), сосудосберегающий план (ССП) до имплантации ПБС (ССП-1), стандартный план после имплантации ПБС без снижения дозы на область сосудистых ЭрКО (СП-2) и сосудосберегающий план после имплантации ПБС (ССП-2). Результаты. Выявлено фактически полное отсутствие изменений в топографии верхушки предстательной железы относительно базальных структур полового члена. Значимых различий по величине радиационной нагрузки на область сосудистых ЭрКО при стандартном планировании (СП-1 и СП-2) независимо от использования ПБС получено не было. Дополнительная оптимизация, направленная на максимальное снижение дозы в рамках протокола сосудосбережения (ССП-1 и ССП-2), обеспечила существенное снижение дозы на область сосудистых ЭрКО по сравнению со стандартными планами, а имплантация ПБС позволила достигнуть наименьших показателей облучения внутренней половой артерии (р < 0,0001). Выводы. Промежностная имплантация ПБС позволяет повысить эффективность сосудосберегающей лучевой терапии РПЖ за счет временного смещения передней стенки прямой кишки относительно предстательной железы, что улучшает оптимизацию пространственного распределения дозы.
- Open Access
- 9 May 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (1) , 35-49
Immediate results of perineal implantation of a prostate-rectum biodegradable spacer
Aim. To evaluate the immediate results of perineal implantation of a biodegradable spacer based on stabilized hyaluronic acid (SНA) of non-animal origin as a way to optimize radiation treatment of prostate cancer.Materials and methods. The study included 48 patients with verified low and intermediate risk prostate cancer per NCCN (National Comprehensive Cancer Network) who received five-fraction stereotactic radiotherapy as radical treatment. Prior to radiotherapy, all patients underwent insertion of a prostate-rectum biodegradable spacer (PRBS) based on synthetic SHA in the volume of 4–8 mL.Results. There were no allergic and inflammatory reactions of tissues to the chemical composition of the implanted PRBS. Despite the invasive nature of the procedure, we did not observe any cases of infectious complications.SНA used in the study demonstrated high levels of hydration (swelling) equal to 24.4 ± 1.5 (20.7–27.3) %, as well as temporal and spatial stability, which determined its optimal characteristics for use as a radiotherapeutic spacer. In all 48 patients, the projected distance (≥1 cm) between the prostate gland and the anterior wall of the rectum was achieved before the start of irradiation. The administration of 4 mL of SНA made it possible to achieve optimal symmetry of the formed space only in one (16.7 %) patient. An increase in the implant volume of the polymer to 6 mL increased the number of such cases to 28.6 %, and after injection of 8 mL it increased to 57 %.The use of PRBS made it possible to reduce radiation dose to the rectum from 21.5 % (D0.1cc (dose per 0.1 cm3 of rectum)) (р 0.0001) to 92.8 % (V75 % (volume receiving 75 % or more of the prescribed dose)) (р 0.0001). Dose reduction for one of the most clinically validated parameters – D2cc (dose to 2 cm3 of rectum)) was 31.5 % (р 0.0001) on average.Conclusion. Perineal implantation of a non-animal SНA (Russia) as a radiotherapy spacer in patients with prostate cancer demonstrates excellent safety and efficacy profiles.
- 9 May 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (1) , 35-49
Open AccessImmediate results of perineal implantation of a prostate-rectum biodegradable spacer
Aim. To evaluate the immediate results of perineal implantation of a biodegradable spacer based on stabilized hyaluronic acid (SНA) of non-animal origin as a way to optimize radiation treatment of prostate cancer.Materials and methods. The study included 48 patients with verified low and intermediate risk prostate cancer per NCCN (National Comprehensive Cancer Network) who received five-fraction stereotactic radiotherapy as radical treatment. Prior to radiotherapy, all patients underwent insertion of a prostate-rectum biodegradable spacer (PRBS) based on synthetic SHA in the volume of 4–8 mL.Results. There were no allergic and inflammatory reactions of tissues to the chemical composition of the implanted PRBS. Despite the invasive nature of the procedure, we did not observe any cases of infectious complications.SНA used in the study demonstrated high levels of hydration (swelling) equal to 24.4 ± 1.5 (20.7–27.3) %, as well as temporal and spatial stability, which determined its optimal characteristics for use as a radiotherapeutic spacer. In all 48 patients, the projected distance (≥1 cm) between the prostate gland and the anterior wall of the rectum was achieved before the start of irradiation. The administration of 4 mL of SНA made it possible to achieve optimal symmetry of the formed space only in one (16.7 %) patient. An increase in the implant volume of the polymer to 6 mL increased the number of such cases to 28.6 %, and after injection of 8 mL it increased to 57 %.The use of PRBS made it possible to reduce radiation dose to the rectum from 21.5 % (D0.1cc (dose per 0.1 cm3 of rectum)) (р 0.0001) to 92.8 % (V75 % (volume receiving 75 % or more of the prescribed dose)) (р 0.0001). Dose reduction for one of the most clinically validated parameters – D2cc (dose to 2 cm3 of rectum)) was 31.5 % (р 0.0001) on average.Conclusion. Perineal implantation of a non-animal SНA (Russia) as a radiotherapy spacer in patients with prostate cancer demonstrates excellent safety and efficacy profiles.
- Open Access
- 14 April 2025
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 16 (1) , 126-138
Flat-detector computed tomographic СО2 arteriohepaticography guided liver biopsy in patient with liver tumor and advanced chronic renal failure: a clinical case
INTRODUCTION: Carbon dioxide (СО2) is a safe contrast agent for patients requiring endovascular and angiography-assisted procedures due to lack of renal toxicity and allergic potential. It is highly important in patients with renal failure and allergies to iodinated contrast agents.OBJECTIVE: To demonstrate a clinical case of percutaneous biopsy guided with the flat-detector computed tomography (FDCT) CO2 arteriohepaticography in the patient with suspected metastatic lesion of the liver, history of cervical squamous cell carcinoma and chronic kidney disease (CKD).MATERIALS AND METHODS: A patient with squamous cell carcinoma of the cervix, due to concomitant kidney pathology (chronic tubulointerstitial nephritis, gouty nephropathy, CKD C4 according to the KDIGO classification) has contraindications for iodinated contrast, hence contrast enhanced computed tomography (CT) and regular FDCT angiography. A native CT study revealed a hypodence 17 mm diameter lesion in SVII of the liver. US and MRI data were ambiguous. The presence of a clear hypervascular rim in the arterial and venous phases of dynamic contrast enhancement could not rule out the metastasis. In order to clarify the nature of the lesion in the liver, multidisciplinary team suggested biopsy under digital subtraction angiography and FDCT arteriohepaticography using CO2 as a contrast agent because of the risk of the haemorrage. For this purpose, using the Seldinger technique, through right femoral artery, by means of an Artis Zee angiographic unit (Siemens, Germany) catheterization and gas subtraction angiography of the common hepatic artery were performed. FDCT-CO2-arteriohepaticography of the common hepatic artery was performed afterwards using the same installation and injecting 30 ml of carbon dioxide at the rate of 3 ml/sec (special «Angiodroid» (Italy) CO2 injector was used) and a scanning delay of 3 sec (in 6sDCT Body mode).RESULTS: Вy means of subtraction CO2-arteriohepaticography and FDCT arteriohepaticography using CO2 in SVII of the liver the solitary hypervascular 15 mm lesion was detected. In order to verify the lesion single-shot US and FDCT-guided biopsy was performed. It was followed by a control FDCT arteriohepaticography using CO2 to exclude bleeding. Histopathology refuted metastasis.CONCLUSION: CO2 is a safe contrast agent in patients with renal failure and allergies to iodinated contrast agents. FDCT CO2 arteriohepaticography is an effective alternative method, that allows safe visualization and bleeding control after interventions in patient with renal failure.
- 14 April 2025
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 16 (1) , 126-138
Open AccessFlat-detector computed tomographic СО2 arteriohepaticography guided liver biopsy in patient with liver tumor and advanced chronic renal failure: a clinical case
INTRODUCTION: Carbon dioxide (СО2) is a safe contrast agent for patients requiring endovascular and angiography-assisted procedures due to lack of renal toxicity and allergic potential. It is highly important in patients with renal failure and allergies to iodinated contrast agents.OBJECTIVE: To demonstrate a clinical case of percutaneous biopsy guided with the flat-detector computed tomography (FDCT) CO2 arteriohepaticography in the patient with suspected metastatic lesion of the liver, history of cervical squamous cell carcinoma and chronic kidney disease (CKD).MATERIALS AND METHODS: A patient with squamous cell carcinoma of the cervix, due to concomitant kidney pathology (chronic tubulointerstitial nephritis, gouty nephropathy, CKD C4 according to the KDIGO classification) has contraindications for iodinated contrast, hence contrast enhanced computed tomography (CT) and regular FDCT angiography. A native CT study revealed a hypodence 17 mm diameter lesion in SVII of the liver. US and MRI data were ambiguous. The presence of a clear hypervascular rim in the arterial and venous phases of dynamic contrast enhancement could not rule out the metastasis. In order to clarify the nature of the lesion in the liver, multidisciplinary team suggested biopsy under digital subtraction angiography and FDCT arteriohepaticography using CO2 as a contrast agent because of the risk of the haemorrage. For this purpose, using the Seldinger technique, through right femoral artery, by means of an Artis Zee angiographic unit (Siemens, Germany) catheterization and gas subtraction angiography of the common hepatic artery were performed. FDCT-CO2-arteriohepaticography of the common hepatic artery was performed afterwards using the same installation and injecting 30 ml of carbon dioxide at the rate of 3 ml/sec (special «Angiodroid» (Italy) CO2 injector was used) and a scanning delay of 3 sec (in 6sDCT Body mode).RESULTS: Вy means of subtraction CO2-arteriohepaticography and FDCT arteriohepaticography using CO2 in SVII of the liver the solitary hypervascular 15 mm lesion was detected. In order to verify the lesion single-shot US and FDCT-guided biopsy was performed. It was followed by a control FDCT arteriohepaticography using CO2 to exclude bleeding. Histopathology refuted metastasis.CONCLUSION: CO2 is a safe contrast agent in patients with renal failure and allergies to iodinated contrast agents. FDCT CO2 arteriohepaticography is an effective alternative method, that allows safe visualization and bleeding control after interventions in patient with renal failure.
- Open Access
- 1 December 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (4) , 33-43
Anatomical aspects of vessel-sparing radiation therapy for prostate cancer
Aim. To assess the impact of topographic anatomy of the critical structures of the penile vessels on the implementation of vessel-sparing radiation therapy for prostate cancer.Materials and methods. The study included 70 patients with verified prostate cancer. All patients underwent topometric computed tomography and magnetic resonance imaging. The target (prostate gland and proximal third of the seminal vesicles), standard critical structures (rectum, bladder, femoral heads), as well as critical vascular structures responsible for erectile function were delineated (bulb of the penis, crura of the corpus cavernosum, internal pudendal artery). The obtained images were subjected to volumetric and spatial analysis using the Eclipse 4.0 (Varian Medical System) planning system.Results. In all 70 patients, adequate visualization of all anatomical structures was achieved. The mean distance between the apex and the penile bulb was 1.35 ± 0.47 (0.35–2.41) cm. In the majority of patients, this index exceeded 1 cm: up to 1 cm – 18 (25.7 %), between 1.1 and 1.5 – 27 (38.6 %), and more than 1.51 cm – 25 (35.7 %). The apical-cavernous distance on the right and left did not differ significantly: 2.05 ± 0.45 (1.12–3.00) and 2.09 ± 0.44 (1.16–3.02) cm, respectively. The internal pudendal artery in the projection of the irradiated volume (prostate gland and proximal third of seminal vesicles) is located at an average distance of 2.5 cm (apex gland) to 4.3 cm (basal parts of the prostate). Analysis (Spearman’s correlation coefficient) did not reveal a significant relationship between the assessed spatial parameters and prostate volume and body mass index.Conclusion. The topographic relationship between the irradiated volumes and erectile vascular structures makes it possible to implement vessel-sparing radiation therapy protocol in the majority of cases (about 75 %).
- 1 December 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (4) , 33-43
Open AccessAnatomical aspects of vessel-sparing radiation therapy for prostate cancer
Aim. To assess the impact of topographic anatomy of the critical structures of the penile vessels on the implementation of vessel-sparing radiation therapy for prostate cancer.Materials and methods. The study included 70 patients with verified prostate cancer. All patients underwent topometric computed tomography and magnetic resonance imaging. The target (prostate gland and proximal third of the seminal vesicles), standard critical structures (rectum, bladder, femoral heads), as well as critical vascular structures responsible for erectile function were delineated (bulb of the penis, crura of the corpus cavernosum, internal pudendal artery). The obtained images were subjected to volumetric and spatial analysis using the Eclipse 4.0 (Varian Medical System) planning system.Results. In all 70 patients, adequate visualization of all anatomical structures was achieved. The mean distance between the apex and the penile bulb was 1.35 ± 0.47 (0.35–2.41) cm. In the majority of patients, this index exceeded 1 cm: up to 1 cm – 18 (25.7 %), between 1.1 and 1.5 – 27 (38.6 %), and more than 1.51 cm – 25 (35.7 %). The apical-cavernous distance on the right and left did not differ significantly: 2.05 ± 0.45 (1.12–3.00) and 2.09 ± 0.44 (1.16–3.02) cm, respectively. The internal pudendal artery in the projection of the irradiated volume (prostate gland and proximal third of seminal vesicles) is located at an average distance of 2.5 cm (apex gland) to 4.3 cm (basal parts of the prostate). Analysis (Spearman’s correlation coefficient) did not reveal a significant relationship between the assessed spatial parameters and prostate volume and body mass index.Conclusion. The topographic relationship between the irradiated volumes and erectile vascular structures makes it possible to implement vessel-sparing radiation therapy protocol in the majority of cases (about 75 %).
- Open Access
- 6 September 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (4)
Mimicry in Oncology: A Rare Clinical Case of Inflammatory Pseudotumor of the Liver
Воспалительная псевдоопухоль печени — редкое поражение с неспецифическими клиническими и лучевыми признаками. Данное заболевание представляет интерес в связи с отсутствием патогномоничной лучевой картины, вследствие этого имитацией злокачественного поражения и возможными ошибками в дифференциальной диагностике. Нами представлено клиническое наблюдение мужчины 47 лет со спонтанным регрессом воспалительной псевдоопухоли печени. Целью клинического наблюдения являлась демонстрация мультимодальной визуализации рассматриваемого заболевания. Несмотря на редкую встречаемость и широкий полиморфизм, врачам различных специальностей следует знать о данной патологии и включать в дифференциально-диагностический ряд при постановке диагноза и выборе тактики дальнейшего ведения пациента.
- 6 September 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (4)
Open AccessMimicry in Oncology: A Rare Clinical Case of Inflammatory Pseudotumor of the Liver
Воспалительная псевдоопухоль печени — редкое поражение с неспецифическими клиническими и лучевыми признаками. Данное заболевание представляет интерес в связи с отсутствием патогномоничной лучевой картины, вследствие этого имитацией злокачественного поражения и возможными ошибками в дифференциальной диагностике. Нами представлено клиническое наблюдение мужчины 47 лет со спонтанным регрессом воспалительной псевдоопухоли печени. Целью клинического наблюдения являлась демонстрация мультимодальной визуализации рассматриваемого заболевания. Несмотря на редкую встречаемость и широкий полиморфизм, врачам различных специальностей следует знать о данной патологии и включать в дифференциально-диагностический ряд при постановке диагноза и выборе тактики дальнейшего ведения пациента.
- Open Access
- 28 December 2022
- Published by Vidar, Ltd. in Medical Visualization
- Vol. 27 (1) , 46-56
Fusion biopsy or real time virtual sonography (RVS) technique – the first experience in verification of hypervascular breast lesions under combined US/MR control
One of the actual problems of oncology is the early diagnosis of breast cancer. However, there are some difficulties not only in diagnostic but also in the verification of lesions. Image-guided cor-biopsy nowadays became the gold standard for verification of non-palpable breast lesions. The main issue is to choose the method of visualization. According to up-to-date recommendations, there is no universal method with all requirements (high visualization quality, convenience, and accessibility for biopsy). Fusion-biopsy or virtual real-time sonography can combine MRI diagnostic potential and facility of US Aim : to leverage the technique of fusion biopsy under combined ultrasound/MR control for verification of breast lesions identified only on MRI and occult on MG and US. Methods. 30 high-risk patients, who had pathological breast lesions detected by diagnostic CE-MRI, classified as BI-RADS 4, 5 yet occult on the other visualization methods were enrolled in the study. All patients underwent supine MRI prebiopsy examination, real-time virtual sonography of the lesions, image-guided biopsy or excisional biopsy, histopathologic examination. Results. The breast fusion-biopsy method was developed based on up-to-date scientific publications and optimized for the technical equipment of N.N. Petrov National Medicine Research Center of Oncology. According to the designed protocol of examination, there were the following steps: interpretation of breast CE-MRI in the standard prone position for breast lesion detection, prebiopsy CE-MRI performed in the supine position, real-time virtual sonography for comparison of breast MRI and US, histopathologic examination. Conclusion. Being one of the perspectives methodic of morphological verification Fusion-biopsy might become a more common procedure in breast lesions diagnostics. The simplicity of US-guided biopsy and high MRI breast diagnostic sensitivity are combined in fusion-biopsy technology.
- 28 December 2022
- Published by Vidar, Ltd. in Medical Visualization
- Vol. 27 (1) , 46-56
Open AccessFusion biopsy or real time virtual sonography (RVS) technique – the first experience in verification of hypervascular breast lesions under combined US/MR control
One of the actual problems of oncology is the early diagnosis of breast cancer. However, there are some difficulties not only in diagnostic but also in the verification of lesions. Image-guided cor-biopsy nowadays became the gold standard for verification of non-palpable breast lesions. The main issue is to choose the method of visualization. According to up-to-date recommendations, there is no universal method with all requirements (high visualization quality, convenience, and accessibility for biopsy). Fusion-biopsy or virtual real-time sonography can combine MRI diagnostic potential and facility of US Aim : to leverage the technique of fusion biopsy under combined ultrasound/MR control for verification of breast lesions identified only on MRI and occult on MG and US. Methods. 30 high-risk patients, who had pathological breast lesions detected by diagnostic CE-MRI, classified as BI-RADS 4, 5 yet occult on the other visualization methods were enrolled in the study. All patients underwent supine MRI prebiopsy examination, real-time virtual sonography of the lesions, image-guided biopsy or excisional biopsy, histopathologic examination. Results. The breast fusion-biopsy method was developed based on up-to-date scientific publications and optimized for the technical equipment of N.N. Petrov National Medicine Research Center of Oncology. According to the designed protocol of examination, there were the following steps: interpretation of breast CE-MRI in the standard prone position for breast lesion detection, prebiopsy CE-MRI performed in the supine position, real-time virtual sonography for comparison of breast MRI and US, histopathologic examination. Conclusion. Being one of the perspectives methodic of morphological verification Fusion-biopsy might become a more common procedure in breast lesions diagnostics. The simplicity of US-guided biopsy and high MRI breast diagnostic sensitivity are combined in fusion-biopsy technology.
- Open Access
- 14 December 2022
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 5 (4) , 54-67
Multiparametric Magnetic Resonance Imaging in Determining Prognostic Factors for Cervical Cancer IB2-IIB Stages after Neoadjuvant Chemotherapy
Мультипараметрическая магнитно-резонансная томография в определении прогностических факторов рака шейки матки IB2-IIB стадий после неоадъювантной химиотерапии
- 14 December 2022
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 5 (4) , 54-67
Open AccessMultiparametric Magnetic Resonance Imaging in Determining Prognostic Factors for Cervical Cancer IB2-IIB Stages after Neoadjuvant Chemotherapy
Мультипараметрическая магнитно-резонансная томография в определении прогностических факторов рака шейки матки IB2-IIB стадий после неоадъювантной химиотерапии